Literature DB >> 2297301

Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients.

D M Novick1, H Joseph, T S Croxson, E A Salsitz, G Wang, B L Richman, L Poretsky, J B Keefe, E Whimbey.   

Abstract

Human immunodeficiency virus (HIV) infection has become widespread among parenteral drug abusers. We measured antibody to HIV and hepatitis B virus markers in 58 long-term, socially rehabilitated methadone-maintained former heroin addicts. None of the 58 had antibody to HIV, but one or more markers of hepatitis B virus infection were seen in 53 (91%). The duration of methadone maintenance was 16.9 +/- 0.5 years, and the median dose of methadone was 60 mg (range, 5 to 100 mg). Before methadone treatment, the patients had abused heroin parenterally for 10.3 +/- 1.7 years, and they had engaged in additional high-risk practices for HIV infection. We conclude that successful outcomes during methadone maintenance treatment are associated with sparing of parenteral drug abusers from HIV infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297301

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  18 in total

Review 1.  HIV prevention among injection drug users: the need for integrated models.

Authors:  David S Metzger; Helen Navaline
Journal:  J Urban Health       Date:  2003-12       Impact factor: 3.671

Review 2.  Drug treatment as HIV prevention: a research update.

Authors:  David S Metzger; George E Woody; Charles P O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

3.  HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial.

Authors:  George E Woody; Douglas Bruce; P Todd Korthuis; Sumedha Chhatre; Sabrina Poole; Maureen Hillhouse; Petra Jacobs; James Sorensen; Andrew J Saxon; David Metzger; Walter Ling
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

Review 4.  Methadone maintenance treatment in opiate dependence: a review.

Authors:  M Farrell; J Ward; R Mattick; W Hall; G V Stimson; D des Jarlais; M Gossop; J Strang
Journal:  BMJ       Date:  1994-10-15

5.  Impact of methadone with versus without drug abuse counseling on HIV risk: 4- and 12-month findings from a clinical trial.

Authors:  Sharon M Kelly; Robert P Schwartz; Kevin E Oʼgrady; Devang Gandhi; Jerome H Jaffe
Journal:  J Addict Med       Date:  2012-06       Impact factor: 3.702

Review 6.  HIV disease in the intravenous drug user: role of the primary care physician.

Authors:  A A Wartenberg
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

Review 7.  Drug abuse treatment as AIDS prevention.

Authors:  D S Metzger; H Navaline; G E Woody
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

8.  Methadone treatment and risk of HIV infection in drug users without legal access to clean injection equipment.

Authors:  V Wietlisbach; G Meystre-Agustoni; J Martin
Journal:  Soz Praventivmed       Date:  1995

Review 9.  Opiate-dependent patients receiving methadone. How physicians should manage therapy.

Authors:  M Kahan; N Sutton
Journal:  Can Fam Physician       Date:  1996-09       Impact factor: 3.275

Review 10.  Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.

Authors:  David M Novick; Mary Jeanne Kreek
Journal:  Addiction       Date:  2008-04-16       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.